Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

On Tuesday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of$ 8.82.The company reported sales of $3.03 billion, down 4%, missing the consensus of$ 3.29 billion.In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including$ 307 million from Eylea HD.Also Read: FDA Sets The Countdown: Regeneron’s Eylea HD Could Be Headed For Major ExpansionNet product sales o ...